Idiopathic Membranous Nephropathy (IMN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Idiopathic Membranous Nephropathy (IMN) Market Outlook

Thelansis’s “Idiopathic Membranous Nephropathy (IMN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Idiopathic Membranous Nephropathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Idiopathic Membranous Nephropathy (IMN) Overview

Membranous nephropathy (MN), also known as membranous glomerulonephritis, is a chronic glomerular disease characterized by specific morphological features observed through light, immunofluorescence (IF), and electron microscopy (EM) analysis of renal tissue. These features include thickening the glomerular basement membrane (GBM) and GBM spikes. Immunostaining reveals granular deposits of IgG and complement along the periphery of glomerular capillary loops, while electron microscopy shows electron-dense subepithelial deposits corresponding to the observed granular IgG staining. MN can be classified into idiopathic or primary MN (IMN or PMN) when secondary factors cannot be identified. IMN, the primary form of MN, is believed to be mediated by IgG antibodies that target podocytes, with IgG4 being the predominant subclass. Several podocyte auto-antigens have been identified in adult IMN, including the M-type receptor for secretory phospholipase A2 (PLA2R1), thrombospondin type-1 domain-containing 7A (THSD7A), and neural epidermal growth factor-like 1 protein (NELL-1). These antigens account for approximately 70-80%, 3-5%, and 5-10% of IMN cases. Recurrence of IMN is observed in approximately half of kidney allograft recipients, resulting in graft dysfunction and failure.

• In the United States, the annual incidence of Membranous Nephropathy is 12 cases per 1 million population.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: